INTRODUCTION {#sec1-1}
============

Postoperative nausea and vomiting (PONV) is the second common complaint with pain being the most common. We searched the online PubMed and Medline databases for articles published in English between 1991 and 2014 using keywords -- postoperative nausea and vomiting, PONV, nausea-vomiting, PONV prophylaxis, and rescue. The review shows that the incidence of PONV is still unacceptably high despite a number of studies on PONV over decades, due to complex mechanism of PONV pathogenesis as well as relative lack of concern regarding this issue. PONV remains a significant problem in modern anesthetic practice because of the adverse consequences such as delayed recovery, unexpected hospital admission, delayed return to work of ambulatory patients, pulmonary aspiration, wound dehiscence, and dehydration.\[[@ref1]\] Considering increasing demand for ambulatory surgery, a holistic approach should be attempted before and during surgery to prevent PONV. The goal of PONV prophylaxis is therefore to decrease the incidence of PONV and thus patient-related distress and reduce health care costs.\[[@ref2][@ref3][@ref4][@ref5]\]

DEFINITION {#sec1-2}
==========

Nausea {#sec2-1}
------

It is an unpleasant sensation referred to a desire to vomit not associated with expulsive muscular movement.\[[@ref6]\]

Vomiting {#sec2-2}
--------

It is the forceful expulsion of even a small amount of upper gastrointestinal contents through the mouth.\[[@ref6]\]

PHYSIOLOGY OF POSTOPERATIVE NAUSEA AND VOMITING {#sec1-3}
===============================================

The pathophysiology of PONV is complex \[[Figure 1](#F1){ref-type="fig"}\]; it involves various pathways and receptors.

![Physiological and pharmacological mechanism of nausea and vomiting. 5HT~3~ - serotonin, H~1~, H~3~ - histamine, M, M1, M3 - muscarinic, D~2~ - dopamine. 5-HT~3~ = 5-hydroxytryptamine subtype 3](AER-10-388-g001){#F1}

There are five primary afferent pathways involved in stimulating vomiting as follows:

The chemoreceptor trigger zone (CTZ)The vagal mucosal pathway in the gastrointestinal systemNeuronal pathways from vestibular systemReflex afferent pathways from the cerebral cortexMidbrain afferents.

Stimulation of one of these afferent pathways can activate the sensation of vomiting via cholinergic (muscarinic), dopaminergic, histaminergic, or serotonergic receptors.\[[@ref7]\]

The neuroanatomical site controlling nausea and vomiting is an ill-defined region called "vomiting center" within reticular formation in the brainstem.\[[@ref8]\] It receives afferent inputs from above-mentioned pathways. Further interactions occur with nucleus tractus solitarius.

Neurokinin-1 (NK-1) receptors are located in area postrema and are thought to play an important role in emesis.\[[@ref8]\]

CTZ is outside blood--brain barrier and is in contact with cerebrospinal fluid (CSF). CTZ enables substances in blood and CSF to interact. Adsorbed toxins or drugs circulating in the blood can cause nausea and vomiting by stimulation of CTZ. Its stimulation can send emetogenic triggers to the brainstem\'s vomiting center to activate the vomiting reflex.

Vomiting center can also be stimulated by disturbance of the gut or oropharynx, movement, pain, hypoxemia, and hypotension.

Efferent signals are directed to glossopharyngeal, hypoglossal, trigeminal, accessory, and spinal segmental nerves.

There is coordinated contraction of abdominal muscles against a closed glottis which raises intra-abdominal and intrathoracic pressures. The pyloric sphincter contracts and the esophageal sphincter relaxes, and there is active antiperistalsis within the esophagus which forcibly expels the gastric contents. This is associated with marked vagal and sympathetic activity leading to sweating, pallor, and bradycardia.

PONV is generally influenced by multiple factors that are related to the patient, surgery, and anesthesia and which requires release of 5-hydroxytryptamine (5-HT) in a cascade of neuronal events involving both the central nervous and gastrointestinal tract. The 5-HT subtype 3 receptor (5-HT~3~) participates selectively in the emetic response.

FACTORS INFLUENCING POSTOPERATIVE NAUSEA AND VOMITING {#sec1-4}
=====================================================

The etiology of emesis is multifactorial. The factors influencing the PONV are as follows:

Patient factorsPreoperative factorsIntraoperative factors:Surgical factorsAnesthesia factorsPostoperative factors

Patient factors {#sec2-3}
---------------

Sex: Women are more likely to experience PONV compared to men. It is the strongest patient-specific predictorMotion sickness: Patients with history of motion sickness or vomiting after previous surgery are at increased risk for PONVSmoking: Nonsmokers are more prone for PONV. In smokers, gradual desensitization of CTZ occursAge: Age \<50 years is a significant risk factor for PONV\[[@ref7]\]Obesity: Recent data suggest that body mass index is not correlated with an increased risk for development of PONV\[[@ref9]\]Delayed gastric emptying: Patients with abdominal pathology, diabetes mellitus, hypothyroidism, pregnancy, increased intracranial tension, history of swallowing blood, and with full stomach are at increased risk of PONV.\[[@ref6]\]

Preoperative factors {#sec2-4}
--------------------

Perioperative fasting: It is uncertain as risk factor\[[@ref7]\]Anxiety: Clinically not relevant for PONV prediction.\[[@ref7]\]

Intraoperative factors {#sec2-5}
----------------------

Surgical factors:Type of surgery: Cholecystectomy and gynecological and laparoscopic surgeries are associated with high incidence of PONV\[[@ref7]\]Duration of surgery: Longer duration surgeries are associated with increased incidence of PONV. Increasing operative duration by 30 min may increase the risk of PONV by 60%.\[[@ref8]\]Anesthesia factors:General anesthesia:\*Nitrous oxide: Significant decrease in postoperative emesis was noted if nitrous oxide was avoided in patients undergoing laparoscopic procedures. Two meta-analyses have demonstrated that avoiding nitrous oxide reduced PONV risk\[[@ref10][@ref11]\] Three mechanisms have been suggested as contributing factors to the increase in postoperative emesis associated with nitrous oxide\[[@ref12]\]1.Stimulation of sympathetic nervous system with catecholamine release\[[@ref13]\]2.Middle ear pressure changes resulting in traction of the membrane of round window and consequent stimulation of the vestibular system\[[@ref14]\]3.Increased abdominal distension resulting from exchange of nitrous oxide and nitrogen in gas introduced into gastrointestinal tract during mask ventilation\[[@ref15]\]\*Inhalational agents: Ether and cyclopropane cause a higher incidence of PONV due to increase in endogenous catecholamines. Sevoflurane, enflurane, desflurane, and halothane are associated with lesser degree of PONV.\[[@ref6]\] Effect of volatile anesthetics on PONV is dose-dependent and prominent in the first 2--6 h after surgery.\[[@ref16]\] Volatile anesthetics were the primary cause of early PONV (0--2 h after surgery); they did not have an impact on delayed PONV (2--24 h after surgery)\[[@ref16]\]\*Etomidate: Continuous etomidate infusion as a part of balanced anesthetic technique markedly increases the incidence of postoperative emesis\[[@ref17]\]\*Ketamine: Studies have shown that ketamine used for induction resulted in delayed discharge, vivid dreams, hallucinations, and higher incidence of PONV compared to a patient receiving barbiturates with nitrous oxide.\[[@ref18]\] Emetic effect is secondary to endogenous catecholamine release\*Propofol: It is popular for outpatient anesthesia due to its favorable recovery characteristics including rapid emergence and reduced PONV\*Balanced anesthesia: Compared to inhalational or total intravenous (IV) technique, the use of nitrous oxide-opioid-relaxant technique is associated with higher incidence of postoperative emesis.\[[@ref12][@ref13][@ref14][@ref15]\] Emesis with balanced anesthesia has been attributed to use of an opioid-nitrous oxide combination, directly stimulating CTZ\*Opioids: It causes emesis through stimulation of opioid receptors located in CTZ. The contribution of intraoperative opioids is weak; there is no difference among different opioids\[[@ref7]\]\*Neuromuscular reversal agents: Incidence of PONV is uncertain.Regional anesthesia: Risk for PONV was 9 times less among patients receiving regional anesthesia than those receiving general anesthesia.\[[@ref19]\] The incidence of postoperative emesis following regional nerve block procedures is usually lower than with general anesthesia.\[[@ref20]\] Emesis with central neuraxial block is greater than that with peripheral nerve block because of associated sympathetic nervous system blockade, which contributes to postural hypotension induced nausea and vomiting.\[[@ref21][@ref22][@ref23][@ref24]\] The incidence of nausea after epidural opioid may be lower with more lipid soluble opioids such as fentanyl and sufentanil, which have less rostral spread from lumbar epidural injection site to CTZ and vomiting center, than the less lipid soluble opioids such as morphine.

POSTOPERATIVE FACTORS {#sec1-5}
=====================

Pain: Visceral or pelvic pain is a common cause of postoperative emesis\[[@ref25][@ref26]\]Ambulation: Sudden motion, changes in position, transport from the postanesthetic recovery unit to the postsurgical ward can precipitate nausea and vomiting in patients who have received opioid compounds\[[@ref25][@ref26][@ref27][@ref28]\]Opioids: Postoperative opioids increase risk for PONV in a dose-dependent manner;\[[@ref29]\] this effect appears to last for as long as opioids are used for pain control in the postoperative period.\[[@ref30]\] Irrespective of route of administration, the incidence of nausea and vomiting appears to be similar. Nonsteroidal anti-inflammatory agents can be used in perioperative period to reduce opioid requirementSupplemental oxygen is no longer recommended for PONV prevention.

PHARMACOGENETICS ASSOCIATED WITH POSTOPERATIVE NAUSEA AND VOMITING {#sec1-6}
==================================================================

The risk of PONV is high in homozygous patients with the A118 variant of OPRM1.\[[@ref31]\] Genes regarded as related to PONV or opioid-induced nausea and vomiting include 5-HT~3~ receptors, muscarinic type-3 receptor, dopamine type 2 receptor, catechol-o-methyl transferase, alpha-2 adrenoceptor, adenosine triphosphate binding cassette subfamily B member, cytochrome P450 superfamily enzyme, and uridine 5'-diphospho-glucuronosyltransferase.\[[@ref31]\]

RISK SCORING SYSTEM {#sec1-7}
===================

A patient\'s baseline risk for PONV should be objectively assessed using a validated score that is based on independent predictors.\[[@ref7]\] The two most commonly used risk scores for inpatient undergoing balanced inhaled anesthesia are the Apfel score and the Koivuranta score.\[[@ref32][@ref33]\]

The Apfel simplified risk score is based on four predictors: female, history of PONV and/or motion sickness, nonsmoking status, and use of postoperative opioids.\[[@ref33]\] The incidence of PONV with the presence of 0, 1, 2, 3, and 4 risk factors is about 10%, 20%, 40%, 60%, and 80%, respectively.\[[@ref33]\] Patients with 0--1, 2 or 3, and more risk factor are considered as "low," "medium," and "high" risk categories, respectively.\[[@ref7]\]

In addition, other clinically relevant aspects should be taken into consideration, such as whether vomiting would pose a significant medical risk, for example, in patients with wired jaws, increased intracranial pressure, and after gastric, or esophageal surgery.\[[@ref7]\]

PHARMACOLOGY: ANTIEMETIC DRUGS {#sec1-8}
==============================

Various drugs are used for the management of PONV. They can be classified based on their action over various receptors \[[Table 1](#T1){ref-type="table"}\].

###### 

Classification of antiemetic drugs based on receptor antagonism

![](AER-10-388-g002)

5-hydroxytryptamine subtype 3 receptor antagonists {#sec2-6}
--------------------------------------------------

These peripherally block gut vagal afferents and act centrally in area postrema. Side effects are headache, mild sedation, dizziness prolongation of QT interval.

### Ondansetron {#sec3-1}

Recommended dose is 4 mg IV at the end of surgery. In 2012, the US Food and Drug Administration (FDA) had recommended that single dose should not exceed 16 mg due to the risk of QT prolongation. The effect of 8 mg oral disintegrating tablet is equivalent to 4 mg IV dose.\[[@ref34][@ref35]\] It is less effective than aprepitant\[[@ref36]\] for reducing emesis and palonosetron for the incidence of PONV.\[[@ref37]\]

### Dolasetron {#sec3-2}

Dose is 12.5 mg IV at the end of surgery. In 2010, the FDA banned the use of dolasetron for chemotherapy-induced nausea and vomiting in adults and children because of concerns of QT c prolongation and torsades de pointes.

### Granisetron {#sec3-3}

Dose 3 mg IV in combination with dexamethasone 8 mg IV is more effective than either drug alone.

### Tropisetron {#sec3-4}

Dose is 2 mg IV at the end of surgery.\[[@ref38]\]

### Ramosetron {#sec3-5}

Dose 0.3 mg IV is most effective to prevent vomiting and decrease nausea for patients receiving fentanyl patient-controlled analgesia (PCA).\[[@ref39]\]

### Palonosetron {#sec3-6}

It is the second generation 5-HT~3~ receptor antagonist with a longer half-life of 40 h.\[[@ref40][@ref41]\] It provokes a conformational change of 5-HT~3~ receptor through allosteric binding. Most effective dose is 0.075 mg IV approved for 24 h.\[[@ref42][@ref43]\]

Anticholinergic/antimuscarinic drugs {#sec2-7}
------------------------------------

They block muscarinic receptors in the cerebral cortex and pons to induce antiemetic effects.\[[@ref31]\]

### Transdermal scopolamine {#sec3-7}

It is a competitive inhibitor at postganglionic muscarinic receptors in the parasympathetic nervous system and acts directly on the central nervous system by antagonizing cholinergic transmission in the vestibular nuclei.\[[@ref31]\] It is applied as transdermal patch due to its short half-life, 1.5 mg is secreted over 72 h. Transdermal scopolamine (TDS) is useful for PONV in setting of PCA.\[[@ref44][@ref45]\] It is applied the evening before surgery or 2--4 h before the start of anesthesia.

Side effects are visual disturbances, dry mouth, and dizziness.

Histamine receptor antagonists {#sec2-8}
------------------------------

These drugs block acetylcholine receptors in the vestibular apparatus and histamine receptors in the nucleus tractus solitarius.\[[@ref31]\]

Side effects are dry mouth, constipation, drowsiness, urinary retention, and blurred vision.

### Dimenhydrinate {#sec3-8}

Dose is 1--2 mg/kg IV.

### Meclizine {#sec3-9}

Dose is 50 mg per orally (PO) plus ondansetron 4 mg IV. It has longer duration of PONV effect than ondansetron.

### Promethazine {#sec3-10}

Dose is 12.5--25 mg IV.

Dopamine antagonist {#sec2-9}
-------------------

### Metaclopramide {#sec3-11}

It is a strong D~2~-receptor antagonist and blocks H~1~ and 5-HT~3~ receptors also. It enhances 5-HT~4~ receptors and upper gastrointestinal tract motility to promote gastric emptying without affecting gastric, biliary, and pancreatic secretion. Intestinal transit time is decreased by increasing duodenal peristalsis. It increases gastroesophageal sphincter tone and decreases pyloric sphincter tone to prevent delayed gastric emptying associated with opioid use. Metoclopramide is a weak antiemetic; dose is 10 mg IV and its side effects include dyskinesia or extrapyramidal symptoms, headache, dizziness, and sedation.

Neurokinin-1 receptor antagonists {#sec2-10}
---------------------------------

It is a new group of drugs used for PONV treatment thought to prevent both acute and delayed emesis.

These act mainly at nucleus tractus solitarius and areas of reticular formation blocking NK-1 receptors. They are more effective in inhibiting emesis than nausea.

### Aprepitant {#sec3-12}

Dose is 40 mg PO 1--2 h prior to surgery. It is an NK-1 receptor antagonist with a 40-h half-life. Aprepitant was significantly more effective than ondansetron for preventing vomiting at 24 h and 48 h after surgery and in reducing nausea severity in the first 48 after surgery.\[[@ref36][@ref46]\]

Side effects are constipation, headache, pyrexia, pruritis.

### Cospitant {#sec3-13}

Dose is 50--150 mg PO plus ondansetron 4 mg, not yet approved for use.

### Rolapitant {#sec3-14}

Dose is 70--200 mg PO and has not been approved for use.

Corticosteroids {#sec2-11}
---------------

### Dexamethasone {#sec3-15}

It blocks the synthesis of prostaglandins, which sensitizes nerves to other commonly involved neurotransmitters in emesis control. It also may have central effect by antagonizing 5-HT~3~ receptors or corticosteroid receptors in the nucleus tractus solitarius. Its side effects are gastrointestinal upset, insomnia.

Preoperative dexamethasone 8 mg enhances the postdischarge quality of recovery in addition to reducing nausea, pain, and fatigue.\[[@ref47]\] It is administered at the time of induction due to relatively slow onset of action. A recent study reported that intraoperative dexamethasone 4--8 mg may confer an increased risk of postoperative infection.\[[@ref48]\] Weighing the risk--benefit ratio, a recent editorial suggests a single dose of dexamethasone 4--8 mg is safe when used for PONV prophylaxis.\[[@ref49]\] Recent studies showed significant increases in blood glucose that occur 6--12 h postoperatively in normal subjects.\[[@ref50][@ref51]\] Those with impaired glucose tolerance,\[[@ref51]\] and type 2 diabetic\[[@ref52]\] and obese\[[@ref51]\] surgical patients receive dexamethasone 8 mg; hence, the use of dexamethasone is relatively contraindicated in labile diabetic patients.

### Methylprednisolone {#sec3-16}

Methyl prednisolone 40 mg IV is effective for prevention of late PONV.\[[@ref53][@ref54]\]

Butryphenones {#sec2-12}
-------------

### Droperidol {#sec3-17}

It is a relatively selective D~2~ receptor antagonist, administered toward the end of the surgery. Its use was stopped in 2001 due to the FDA "black box" restriction in view of significant cardiovascular events. A recent meta-analysis suggests that with prophylactic low-dose droperidol (\<1 mg or 15 µg/kg IV) in adults, there is still significant antiemetic efficacy with a low risk of adverse effects.\[[@ref55]\]

### Haloperidol {#sec3-18}

Haloperidol \< 2 mg reduces the risk of side effects and QT prolongation.\[[@ref56]\] It is not FDA approved.

Phenothiazines {#sec2-13}
--------------

### Perphenazine {#sec3-19}

It prevents PONV at doses between 2.5 and 5 mg IV or IM.\[[@ref57]\]

### Chlorpromazine {#sec3-20}

It is a D~2~ receptor antagonist at CTZ and dosage is 10 mg IV; its side effect is severe sedation.

Other antiemetics {#sec2-14}
-----------------

### Propofol {#sec3-21}

It is used as part of total intravenous anesthesia (TIVA) to reduce baseline risk of PONV. Propofol has antiemetic properties even with subhypnotic dose range. Median plasma propofol concentration associated with antiemetic effect was 343 ng/ml, which is much less than sedation (1--3 mcg/ml) and induction (3--6 mcg/ml) plasma propofol concentration.\[[@ref58]\]

### Alpha-2-agonists {#sec3-22}

These possess a direct antiemetic effect along with opioid-sparing effect. In a meta-analysis, perioperative systemic alpha-2-adrenoceptor agonists (clonidine and dexmedetomidine) showed a significant albeit weak and short-lived antinausea effect.\[[@ref59]\]

### Mirtazepine {#sec3-23}

It is a specific serotonergic and noradrenergic antidepressant. The combination of mirtazapine 30 mg PO and dexamethasone 8 mg reduces the incidence of late PONV \>50%.

### Gabapentin {#sec3-24}

Gabapentin dose of 600 mg PO given 2 h before surgery effectively decreases PONV.\[[@ref60][@ref61][@ref62]\] Given an hour before surgery, gabapentin 800 mg PO is as effective as dexamethasone 8 mg IV, and the combination is better than either drug alone.\[[@ref63]\]

### Midazolam {#sec3-25}

Midazolam 2 mg when administered 30 min before the end of the surgery was as effective against PONV as ondansetron 4 mg.\[[@ref64]\] Midazolam 2 mg given 30 min before end of the surgery decreased PONV more effectively than midazolam 35 mcg/kg premedication.\[[@ref65]\]

### Intravenous fluids {#sec3-26}

Adequate IV fluid hydration is an effective strategy for reducing the baseline risk for PONV. There is no difference between crystalloids and colloids when similar volumes were used in surgeries associated with minimal fluid shifts.\[[@ref7]\]

Nonpharmacological management of postoperative nausea and vomiting {#sec2-15}
------------------------------------------------------------------

Acupuncture\*P~6~-stimulation with 10 different acupuncture modalities reduces nausea and vomiting. Neuromuscular stimulation over median nerve reduces the incidence of PONV in early postoperative period.\[[@ref66][@ref67]\]Acupoint stimulationAcupressureTranscutaneous electrical nerve stimulationElectroacupuncture.

CLINICAL APPLICATION - MANAGEMENT OF POSTOPERATIVE NAUSEA AND VOMITING {#sec1-9}
======================================================================

Strategies not effective for postoperative nausea and vomiting prevention {#sec2-16}
-------------------------------------------------------------------------

Strategies not effective for PONV prevention are music therapy, isopropyl alcohol inhalation, intraoperative gastric decompression, the proton pump inhibitor (esomeprazole), ginger root, nicotine patch to nonsmokers, and cannabinoids (nabilone and tetrahydrocannabinol).\[[@ref7]\]

Combination antiemetic therapy {#sec2-17}
------------------------------

Combination therapy for PONV prophylaxis is preferable to using a single drug alone.\[[@ref68][@ref69]\] The combination of drugs from different classes with different mechanism of action are administered for optimized efficacy in adults with moderate to high risk for PONV.

Pharmacologic combination therapy that can be used are as follows:\[[@ref7]\]

Droperidol and dexamethasone5-HT~3~ receptor antagonist and dexamethasone5-HT~3~ receptor antagonist and droperidol5-HT~3~ receptor antagonist and dexamethasone and droperidol.

The 5-HT~3~ antagonists have better antiemetic than antinausea efficacy but are associated with headache. These drugs can be used in combination with droperidol which has greater antinausea efficacy and is associated with lower risk of headache.\[[@ref70]\] The 5-HT~3~ antagonists can also be effectively combined with dexamethasone.\[[@ref71]\] It has been suggested that when used as combination therapy, dexamethasone doses should not exceed 10 mg IV, droperidol doses should not exceed 1 mg IV, and ondansetron doses in adults should not exceed 4 mg and can be much lower.\[[@ref72]\]

Multimodal approach {#sec2-18}
-------------------

Multimodal approach combines nonpharmacologic and pharmacologic prophylaxis along with interventions that reduce baseline risk. A planned multimodal approach starting from preoperative period can significantly reduce the incidence of PONV.\[[@ref73]\] A multimodal approach to reduce PONV consisting of preoperative anxiolysis (midazolam), prophylactic antiemetics (droperidol at induction and ondansetron at end of surgery), TIVA with propofol, and local anesthetic infiltration, and ketorolac with no nitrous oxide usage had a 80% complete response rate compared with 43% to 63% response rate among patients receiving either inhaled drug, or TIVA alone.\[[@ref74]\]

Postoperative nausea and vomiting prophylaxis and rescue {#sec2-19}
--------------------------------------------------------

Depending on the level of risk, prophylaxis should be initiated with monotherapy or combination therapy using interventions that reduce baseline risk, nonpharmacologic approach, and antiemetics.\[[@ref7]\]

No prophylaxis is recommended for patients at low risk for PONV except if they are at risk of medical consequences from vomiting, for example, patients with wired jaw.\[[@ref8]\]

Antiemetic prophylaxis, although cannot eliminate the risk for PONV, can significantly reduce incidence. When developing management strategy for each individual patient with moderate and high risk, the choice should be based on patient preference, cost efficiency, level of PONV risk, patient\'s pre-existing condition (avoid QT-prolonging drugs in patients with QT-syndrome and TDS in closed angle glaucoma patients).\[[@ref7]\]

The rescue therapy should be initiated when the patient complaints of PONV, and the same time, an evaluation should be performed to exclude inciting medications or mechanical factor for nausea and/or vomiting such as opioid PCA, blood draining down the throat, or an abdominal obstruction.

When rescue therapy is required, the antiemetics should be chosen from a different therapeutic class than the drugs used for prophylaxis, or if no prophylaxis was given, the recommended treatment is low-dose 5-HT~3~ antagonist. The dose of 5-HT~3~ antagonist used for treatment is smaller than those used for prophylaxis (ondansetron 1 mg, granisetron 0.1 mg, and tropisetron 0.5 mg).\[[@ref10]\] If PONV occurs within 6 h postoperatively, patient should not receive a repeat dose of prophylactic antiemetic. An emetic episode more than 6 h postoperatively can be treated with any of the drugs used for prophylaxis except dexamethasone, TDS, aprepitant, and palonosetron.\[[@ref7]\]

CONCLUSION {#sec1-10}
==========

The understanding of PONV mechanism and careful assessment of risk factors helps in PONV management. PONV prophylaxis should be considered for patients with moderate to high risk based on scoring system. Based on the level of risk, the patient can be treated with monotherapy or combination therapy of antiemetics along with nonpharmacologic approach and interventions for reducing baseline risk. A planned multimodal approach starting from preoperative period most likely ensures success in the management of PONV, which significantly improves the quality of patient care and is cost-effective.
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